SCHEDULE 13G/A: BlackRock Discloses 6.4% Stake in Arcellx, Inc. Common Stock
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.4% of Arcellx, Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 3,527,220 shares of Arcellx, Inc. Common Stock.
- This stake represents 6.4% of the total outstanding common shares of Arcellx, Inc.
- BlackRock holds sole voting power over 3,484,513 shares and sole dispositive power over 3,527,220 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership position.
- The event date that triggered this filing was March 31, 2025.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Arcellx, Inc.
- The aggregate ownership includes holdings by various BlackRock business units and subsidiaries, with at least one entity beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: The disclosure of a significant, passive stake by a major institutional investor like BlackRock is generally viewed positively as it implies confidence in the company. There are no negative aspects reported in the filing itself.
Positives
- A significant institutional investor like BlackRock holding a 6.4% stake can be viewed as a vote of confidence in Arcellx, Inc.'s long-term prospects.
- The stated purpose of the holding is in the ordinary course of business, suggesting a passive investment rather than an activist stance, which can provide stability.
Industry Context
This filing reflects a routine disclosure by a major asset manager, BlackRock, regarding its passive investment stake in Arcellx, Inc. It does not provide specific insights into broader industry trends but indicates continued institutional interest in the biotechnology or healthcare sector, where Arcellx likely operates given its name.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by BlackRock may increase investor confidence and potentially influence trading activity, as it signals a major player's belief in the company's value.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the current filing. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-04-17 | Date the Schedule 13G was signed and filed with the SEC. |
Keywords
Arcellx Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.